中國醫療集團(8225.HK)再創歷史新高 三連陽累漲約30倍
格隆匯1月31日丨中國醫療集團(8225.HK)今日再度大漲,盤中股價一度漲超80%高至3.91港元,再創歷史新高,現漲幅為64.29%,報3.45港元,暫成交3.7億港元,最新總市值為34.25億港元。該股近日遭資金爆炒,股價三連陽,累積漲幅約30倍。

中國醫療集團近日公佈,中國科學院武漢病毒研究所發現利托那韋在細胞層面上對新型冠狀病毒有較好抑制作用。目前集團關聯公司萬全萬特廈門有限公司是一家唯一國內歷史生產過該產品製劑,企業同時擁有原料批文,申請相關專利和已經向國家藥監局申請重新恢復生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.